Frontotemporal Dementia and Pharmacologic Interventions

Kaye, Edward D.; Petrovic-Poljak, Ana; Verhoeff, N. P. L. G.; Freedman, Morris

doi:10.1176/jnp.2010.22.1.19

Cited by 29 publications

(26 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients were divided into the following groups according to their MMSE score: Mild bvFTD (MMSE score, 21-26); and moderate-to-severe bvFTD (MMSE score, [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20].…”

Section: Study Design and Diagnostic Proceduresmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six-month, open-label, self-controlled clinical trial

Pan

Quan

Zhou

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Previous studies have focused on the curative effects of memantine in patients with mild-to-moderate frontotemporal lobar degeneration (FTLD); however, its benefits in patients with moderate-to-severe FTLD have not been investigated. The present study explores the behavioral, cognitive and functional effects of memantine on behavioral variant frontotemporal dementia (bvFTD) in patients with mild and moderate-to-severe stage bvFTD. A total of 42 patients with bvFTD completed a 6-month treatment plan of 20 mg memantine daily in an open-label, self-controlled clinical trial. Patients were divided into two groups according to their Mini-Mental State Examination (MMSE) score: Mild (score, 21-26); and moderate-to-severe (score, 4-20). Primary endpoints included Neuropsychiatric Inventory Questionnaire (NPI-Q) and Clinic Dementia Rating (CDR) scores, and secondary endpoints comprised Neuropsychiatric Inventory Caregiver Distress Scale (NPI-D), MMSE, Montreal Cognitive Assessment (MoCA), Activity of Daily Life (ADL) and Hamilton Depression Rating Scale (HAMD) scores. Memantine treatment had no effect on overall NPI-Q scores, with the exception of the agitation subdomain in all patients with bvFTD. However, patients with moderate-to-severe bvFTD exhibited a better performance than patients with mild bvFTD, demonstrated by improved NPI-Q total scores and subscales of agitation, depression, apathy and disinhibition. In the moderate-to-severe group, CDR and HAMD scores remained stable, but MMSE, MoCA and ADL scores were reduced after 6 months of treatment. Memantine was well-tolerated in patients. In conclusion, patients with moderate-to-severe bvFTD responded significantly better to memantine in comparison to patients with mild bvFTD with regard to their neuropsychiatric scores, while memantine did not present any cognitive or functional benefits in patients with mild bvFTD. A randomized, double-blind, placebo-controlled clinical trial with a larger number of patients is required to verify these promising results for patients with moderate-to-severe bvFTD.

show abstract

Section: Study Design and Diagnostic Proceduresmentioning

confidence: 99%

“…This creates challenges for the establishment of an optimal pharmacological disease management model. To date, the U.S. Food and Drug Administration (FDA) has not approved any pharmacological treatments that specifically target FTLD and alter the course of the disease (4).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six-month, open-label, self-controlled clinical trial

Pan

Quan

Zhou

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…Although cholinesterase inhibitors have been studied in many types of dementia, approval is limited to Alzheimer's disease and Parkinson's disease. There is anecdotal evidence that cholinesterase inhibitors may be ineffective or cause clinical worsening in frontal temporal dementia [ 4 ] . Although not approved for treatment of mild cognitive impairment (MCI), several trials have demonstrated the bene fi t of cholinesterase inhibitors on cognitive, functional, and global clinical outcomes.…”

Section: Treating Dementiamentioning

confidence: 99%

After the Diagnosis of Dementia: Considerations in Disease Management

Hoover

Sano

2012

Handbook on the Neuropsychology of Aging and Dementia

View full text Add to dashboard Cite

Once diagnosed with Alzheimer's disease or related disorders, patients and caregivers must integrate treatment and management plans. While there are no cures for these disorders, there are opportunities to optimize function and quality of life. There are pharmacological treatments available for dementia as well as for the behavioral and psychiatric symptoms that often accompany these diagnoses. Persistence can insure that drug treatments provide optimal bene fi t. Also nonpharmacological interventions including environmental modi fi cations can be helpful, particularly for the behavioral problems. Supervision to insure adequate medical care, maximize independence and social interaction, and preserve patient dignity will require ongoing review of the patient's changing condition. A comprehensive approach to management will also consider legal and fi nancial needs, support for the caregiver, and the possibility of research participation. Clinicians can introduce the possibility of research for the hope it offers to their patients and to the generations to come.

show abstract

“…Large, randomized, double-blind studies are lacking. The treatment of FTD is, in general, a work in progress [85].…”

Section: Treatment Of Ftd and Ppamentioning

confidence: 99%

Frontotemporal Dementia and Primary Progressive Aphasia: An Update

Kirshner

2010

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Frontotemporal dementias are syndromes of progressive dysfunction of the frontal and/or temporal lobes, either unilaterally or bilaterally. These syndromes were described clinically under the terms "primary progressive aphasia" in the United States and "frontotemporal dementia" in Europe and the United Kingdom. They are diagnosed by the clinical features of a frontal lobe neurobehavioral syndrome, or a language and cognitive deterioration. In recent years, molecular genetic findings in these syndromes, especially the tau and progranulin mutations on chromosome 17, have provided a molecular and genetic foundation for the understanding of frontotemporal dementia. These disorders are distinct from Alzheimer's disease but have some overlap with the syndrome of corticobasal degeneration, and with motor neuron disease. Treatments remain very limited, mainly involving therapy for the mood and behavioral symptoms, but advances in the molecular and genetic understanding of these conditions will hopefully lead to more specific therapies in the future.

show abstract

Frontotemporal Dementia and Pharmacologic Interventions

Cited by 29 publications

References 96 publications

Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six-month, open-label, self-controlled clinical trial

Efficacy of memantine on neuropsychiatric symptoms associated with the severity of behavioral variant frontotemporal dementia: A six-month, open-label, self-controlled clinical trial

After the Diagnosis of Dementia: Considerations in Disease Management

Frontotemporal Dementia and Primary Progressive Aphasia: An Update

Contact Info

Product

Resources

About